(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Web designers for Independent ventures - 2Foods with healthy-sounding buzzwords could be hiding added sugar in plain sight
- 3‘Trip of suffering’: Gaza evacuee details 24-hour journey to South Africa
- 4Data centers in space: Will 2027 really be the year AI goes to orbit?
- 5Journalists killed by Israeli strike in southern Lebanon
- Must-Have Wellness Gear: What to Purchase for Successful Exercises
- Most loved Web-based feature: Which Stage Do You Like
- CRP Subsea secures contract for Vattenfall’s Nordlicht I cable systems
- Top 20 Wellbeing and Wellness Applications for a Sound Way of life
- Astounding Treehouses All over the Planet
- Von der Leyen: Paris meeting sends signal of unity for Ukraine
- Sound Propensities: 20 Methods for helping Your Insusceptible Framework
- Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push
- Figure out how to Separate Among Fledgling and Master Fender bender Legal counselors
